Maen Hussein

5.4k total citations · 4 hit papers
46 papers, 2.9k citations indexed

About

Maen Hussein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Maen Hussein has authored 46 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Maen Hussein's work include Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Research Studies (16 papers). Maen Hussein is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Research Studies (16 papers). Maen Hussein collaborates with scholars based in United States, United Kingdom and Switzerland. Maen Hussein's co-authors include Federico Cappuzzo, Henry Jacob Conter, Alan Sandler, Niels Reinmuth, Marcin Kowanetz, Davey B. Daniel, Michael McCleod, Alessandro Morabito, Hans‐Georg Kopp and Tarek Mekhail and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Maen Hussein

44 papers receiving 2.8k citations

Hit Papers

Atezolizumab in combination with carboplatin plus nab-pac... 2019 2026 2021 2023 2019 2020 2022 2022 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
  2. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
    2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →
  3. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
    2022 296 citations Byoung Chul Cho, Delvys Rodríguez‐Abreu et al. The Lancet Oncology profile →
  4. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
    2022 238 citations Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maen Hussein United States 15 2.5k 1.7k 642 249 224 46 2.9k
Alexander I. Spira United States 10 2.2k 0.9× 1.3k 0.8× 636 1.0× 228 0.9× 384 1.7× 19 2.5k
Shelley Coleman United States 7 2.8k 1.1× 1.9k 1.2× 599 0.9× 399 1.6× 387 1.7× 10 3.2k
Ryan D. Gentzler United States 20 2.1k 0.8× 1.4k 0.8× 426 0.7× 285 1.1× 219 1.0× 86 2.5k
C. Lewanski United Kingdom 16 2.4k 1.0× 1.7k 1.0× 587 0.9× 354 1.4× 389 1.7× 41 3.0k
Michael McCleod United States 17 2.5k 1.0× 1.7k 1.0× 341 0.5× 410 1.6× 276 1.2× 44 3.0k
Yun Shen United States 25 2.2k 0.9× 1.1k 0.7× 848 1.3× 332 1.3× 346 1.5× 46 2.8k
Caicun Zhou China 25 1.4k 0.6× 1.3k 0.8× 259 0.4× 389 1.6× 360 1.6× 39 2.0k
Kristen A. Marrone United States 16 1.5k 0.6× 761 0.5× 418 0.7× 458 1.8× 190 0.8× 74 2.0k
Leila Khoja United Kingdom 20 1.7k 0.7× 612 0.4× 403 0.6× 416 1.7× 388 1.7× 50 2.1k
Jerome H. Goldschmidt United States 16 1.3k 0.5× 1.0k 0.6× 241 0.4× 356 1.4× 160 0.7× 68 1.9k

Countries citing papers authored by Maen Hussein

Since Specialization
Citations

This map shows the geographic impact of Maen Hussein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maen Hussein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maen Hussein more than expected).

Fields of papers citing papers by Maen Hussein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maen Hussein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maen Hussein. The network helps show where Maen Hussein may publish in the future.

Co-authorship network of co-authors of Maen Hussein

This figure shows the co-authorship network connecting the top 25 collaborators of Maen Hussein. A scholar is included among the top collaborators of Maen Hussein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maen Hussein. Maen Hussein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hussein, Maen, Gazala Khan, Sreenivasa R Chandana, et al.. (2024). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.. Journal of Clinical Oncology. 42(16_suppl). 4136–4136. 2 indexed citations
2.
3.
Lee, Elizabeth, Jordi Rodón, Michael J. Demeure, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300). Gynecologic Oncology. 176. S185–S185. 1 indexed citations
4.
Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2023). Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 186. 107422–107422. 4 indexed citations
5.
Kanack, Adam J., Jordan K. Schaefer, Meera Sridharan, et al.. (2023). Monoclonal gammopathy of thrombotic/thrombocytopenic significance. Blood. 141(14). 1772–1776. 15 indexed citations
6.
Ahn, Myung‐Ju, Igor Bondarenko, Ewa Kalinka‐Warzocha, et al.. (2023). Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. Journal of Thoracic Oncology. 18(11). 1594–1606. 8 indexed citations
7.
Iyer, Gopa, Michael J. Demeure, Dustin A. Deming, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).. Journal of Clinical Oncology. 41(6_suppl). TPS597–TPS597.
8.
Deming, Dustin A., Jordi Rodón, Michael J. Demeure, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).. Journal of Clinical Oncology. 41(4_suppl). TPS818–TPS818. 1 indexed citations
9.
10.
Johnson, Melissa L., Byoung Chul Cho, Alexander Luft, et al.. (2022). Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology. 41(6). 1213–1227. 238 indexed citations breakdown →
11.
Cho, Byoung Chul, Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2022). Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. The Lancet Oncology. 23(6). 781–792. 296 indexed citations breakdown →
12.
Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2022). 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Annals of Oncology. 33. S29–S30. 2 indexed citations
13.
14.
15.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →
16.
McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations
17.
Richards, Donald, Maen Hussein, Steven McCune, et al.. (2018). What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.. Journal of Clinical Oncology. 36(15_suppl). e20567–e20567. 1 indexed citations
18.
Spigel, David R., Lee S. Schwartzberg, David Waterhouse, et al.. (2017). P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153. Journal of Thoracic Oncology. 12(1). S1287–S1288. 39 indexed citations
19.
Johnson, Melissa L., Volker Wacheck, Maen Hussein, et al.. (2016). A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi441–vi441. 3 indexed citations
20.
Hussein, Maen, Donald Richards, Brian Ulrich, et al.. (2016). ORAL01.02: Biopsies in Initial Diagnosis of Non–Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy. Journal of Thoracic Oncology. 11(11). S249–S250. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander I. Spira Breakdown of academic impact, for papers by Shelley Coleman Breakdown of academic impact, for papers by Ryan D. Gentzler Breakdown of academic impact, for papers by C. Lewanski Breakdown of academic impact, for papers by Michael McCleod Breakdown of academic impact, for papers by Yun Shen Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Kristen A. Marrone Breakdown of academic impact, for papers by Leila Khoja Breakdown of academic impact, for papers by Jerome H. Goldschmidt
Rankless by CCL
2026